Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
08/2003
08/21/2003CA2474670A1 Diagnostic method for stroke
08/21/2003CA2472956A1 Formulation strategies in stabilizing peptides in organic solvents and in dried states
08/21/2003CA2471392A1 Method for the generation of genetically modified vertebrate precursor lymphocytes and use thereof for the production of heterologous binding proteins
08/21/2003CA2452854A1 Identification of actinobacillus actinomycetemcomitans antigens for use in the diagnosis, treatment, and monitoring of periodontal diseases
08/21/2003CA2372316A1 The use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock
08/20/2003EP1336847A1 Cathepsin Y inhibitors for the development of a medicament for the treatment of pain
08/20/2003EP1336619A2 Combination of a HVEM-LIGHT inhibitor and an immunosuppressive agent in the treatment or prevention of immune disorders
08/20/2003EP1336618A1 Porcine complement regulator factor H and its use
08/20/2003EP1336617A2 Conotoxins having acetylcholin receptor binding properties
08/20/2003EP1336616A1 Activated peptides and conjugates
08/20/2003EP1336600A2 Dimer-selective RXR modulators and methods for their use
08/20/2003EP1336411A1 Compositions and methods for improving enzyme replacement therapy of lysosomal storage diseases
08/20/2003EP1336410A1 Protein injection preparations
08/20/2003EP1336409A1 Compositions and formulations for producing analgesia and for inhibiting progression of neuropathic pain disorders
08/20/2003EP1335976A2 Modifier of organelle metalbolism
08/20/2003EP1335975A2 "47324", a human g-protein and uses therefor
08/20/2003EP1335938A2 Apolipoprotein analogues
08/20/2003EP1335937A2 Mixed fibrils
08/20/2003EP1335933A2 Pna analogues
08/20/2003EP1335932A1 Isolation of lectins
08/20/2003EP1335931A2 Derivatisation of proteins in aqueous solution
08/20/2003EP1335901A1 Pharmaceutically active sulfanilide derivatives
08/20/2003EP1335895A2 Protease inhibitors and their pharmaceutical uses
08/20/2003EP1335771A2 Methods and instruments for treating pseudoarthrosis
08/20/2003EP1335752A1 Multipurpose packages for sterilised products or products to be sterilised
08/20/2003EP1335745A1 Use of a compound antagonist of the esm-1 protein for producing a medicine for treating cancer
08/20/2003EP1335743A1 Inhibition or reversal of skin aging by actin-sequestering peptides
08/20/2003EP1335741A2 METHODS OF TREATMENT OR PREVENTION OF AUTOIMMUNE DISEASES WITH CpG-CONTAINING POLYNUCLEOTIDE
08/20/2003EP1335733A1 Treatment of osteoporosis
08/20/2003EP1335706A2 Microspheres of pancreatic enzymes with high stability
08/20/2003EP1239836B1 Colloidal suspension of submicronic particles as vectors for active principles and method for preparing same
08/20/2003EP1212327B1 Pyrazolopyrimidines as therapeutic agents
08/20/2003EP1147213A4 Novel rgs-containing molecules and uses thereof
08/20/2003EP1146892B1 Baff, inhibitors thereof and their use in the modulation of the b-cell response
08/20/2003EP1093381B1 Antigenic peptides derived from telomerase
08/20/2003EP1047711B1 Nucleic acid sequences encoding capsaicin receptors
08/20/2003EP0868511B1 Utrophin gene expression
08/20/2003EP0865288B1 Bioartificial devices and cellular matrices therefor
08/20/2003EP0861091B1 Immunotoxin containing a disulfide-stabilized antibody fragment
08/20/2003EP0859591B1 Use of at least one no synthase inhibitor for treating sensitive skin
08/20/2003EP0821003B1 Peptides and remedy for autoimmune diseases comprising the same
08/20/2003EP0721510B1 Anti-cancer gene therapy by modulation of immune or inflammatory response
08/20/2003EP0697886B1 New peptide antagonists at glutamate and nmda receptors
08/20/2003EP0672067B1 Dna encoding a prostaglandin receptor, a host cell transformed therewith and an expression product thereof
08/20/2003CN2566851Y Nano-insulin oral preparation
08/20/2003CN1437652A Compounds and methods for treatment and diagnosis of chlamydial infection
08/20/2003CN1437634A The preparation method of a stable polymer aqueous phase-aqueous phase emulsion and its use
08/20/2003CN1437611A 糖肽膦酸盐衍生物 Glycopeptide phosphonate derivatives
08/20/2003CN1437608A O-aryl glucoside SGL T2 inhibitors and method
08/20/2003CN1437481A QS-21 and IL-12 as an adjuvant combination
08/20/2003CN1437479A Recombinant intracellular pathogen vaccines and methods for use
08/20/2003CN1437478A Intrathecal administration of Rituximab for treatment of central nervous system lymphomas
08/20/2003CN1437477A A Memory enhancing protein
08/20/2003CN1437466A Methods for pulmonary delivery of interleukin-2
08/20/2003CN1437442A Peptide analogs and mimetics suitable for in vivo use in the treatment of diseases associated with abnormal protein folding into amyloid, amyloid-like deposits or beta-sheet rich pathological
08/20/2003CN1436847A Chinese human thymosin-alpha source and its prepn
08/20/2003CN1436792A Tumor necrosis factor relative cell death inducing ligand extracellular region mutation polypeptide and its prepn and use
08/20/2003CN1436571A Thrombosis resisting composition
08/20/2003CN1436570A Production process and application of improved human alpha-interferon
08/20/2003CN1118573C Non-splicing variants of gp 350/220
08/20/2003CN1118572C G-CSF analogue compisition, and preparing process thereof
08/20/2003CN1118571C Active protein with thrombopoietin
08/20/2003CN1118475C Cyclopeptide derivatives
08/20/2003CN1118458C Pyrimidinyl derivatives as interleukin inhibitors
08/20/2003CN1118299C Gonococcal anti-idiotypic antibodies and using methods and composition thereof
08/20/2003CA2372744A1 A method for extraction and purification of cartilage type proteoglycan
08/19/2003WO2003070947A1 Apoptosis promoter and inhibitor interacting with cgi-94 and method of screening the same
08/19/2003US6608204 Peptide aldehyde having arginine or arginine mimics at P1 and pyridone, pyrimidone, or uracil groups; antithrombosis agents
08/19/2003US6608203 Tetrahydroisoquinoline compounds as estrogen agonists/antagonists
08/19/2003US6608196 Structurally diverse; parallel approach
08/19/2003US6608192 Collections of compounds
08/19/2003US6608191 Antisense oligonucleotide of given sequence; capable of inhibiting the function of viral RNA
08/19/2003US6608187 C1 bacteriophage lytic system
08/19/2003US6608182 Human vascular endothelial growth factor 2
08/19/2003US6608177 Mutation of serine replaced with cysteine; use as anti-HIV, anti-allergic or anti- inflammatory agents
08/19/2003US6608175 Oxadiazole, thiadiazoles or triazole metal derivatives reacted with an amine containing aldehyde, deprotecting, coupling with an acid and oxidizing to create substituted oxadiazole, thiadiazole or triazole peptoids
08/19/2003US6608174 Of given amino acid sequence; radionuclides; use as scintigraphic imaging agents for visualization of tumors and metastasis
08/19/2003US6608173 Method for searching physiologically active substances, process for producing these substances and drugs found by the searching method
08/19/2003US6608100 HIV protease inhibitors based on amino acid derivatives
08/19/2003US6608089 Derivatives of flavones, xanthones and coumarins
08/19/2003US6608063 For example: (2-(3-amino-4-nitrophenyl)amino)ethyl)(6-(2,4-dichlorophenyl-5-nitropyrazin -2-yl)-amine; antidiabetic, -carcingenic and ischemic agents; nervous and cardiovascular system disorders; immunotherapy; obesity; syndromes
08/19/2003US6608044 Inhibition of TNF activity
08/19/2003US6608038 Methods and compositions for treatment of diabetes and related conditions via gene therapy
08/19/2003US6608035 Orally administering to mammal oligonucleotide of 15 to 30 nucleotides, comprising phosphorothioate linkages between nucleosides and 2'-O-alkoxyalkyl-ribonucleotides at each end, whereby oligonucleotide is intact in liver and kidney tissue
08/19/2003US6608031 Peptide comprising specified amino acid sequence
08/19/2003US6608030 Inhibitor of cathepsin S based upon peptide sequence which comprises at least about 2-20 consecutive residues from preferred invariant chain cleavage site of cathepsin S, spanning from residue 68 to residue 90 of specified sequence
08/19/2003US6608029 Reducing gastric motility or delaying gastric emptying in mammal by administering therapeutically effective amount of amylin or amylin agonist, such as pramlintide or pramlintide acetate
08/19/2003US6608028 Insulin-like growth factor agonist molecules
08/19/2003US6608027 Macrocyclic peptides active against the hepatitis C virus
08/19/2003US6607916 Antisense inhibition of Casein kinase 2-alpha expression
08/19/2003US6607915 Antisense inhibition of E2A-Pbx1 expression
08/19/2003US6607913 Vertebrate embryonic pattern-inducing proteins and uses related thereto
08/19/2003US6607899 Amplifying and isolating preferential nucleotide sequences; obtain preferential nucleotide sequence library, incubate with primers, amplify nucleotide sequences, digest, recover preferential nucleotide sequences
08/19/2003US6607897 Reptile venom polypeptide for use in reduction of complement activity
08/19/2003US6607884 Oligonucleotide probes; hybridization; polynucleotides; use for modulating muscle cell and adipose tissue growth and detection of cell proliferative disorder of muscle, nerve or fat tissues
08/19/2003US6607882 Regulation of endogenous gene expression in cells using zinc finger proteins
08/19/2003US6607880 Methods and reagents for modulating apoptosis
08/19/2003US6607743 Milk-derived basic cystatins or decomposition products; foods, beverages, feeds
08/19/2003US6607731 Fusion protein; vaccines
08/19/2003US6607729 Surface antigen
1 ... 1790 1791 1792 1793 1794 1795 1796 1797 1798 1799 1800 1801 1802 1803 1804 1805 1806 1807 1808 1809 1810 ... 3163